Tag: Paula Sherriff

The below Parliamentary question was asked by Paula Sherriff on 2016-03-15.

To ask the Secretary of State for Health, what estimate his Department has made of the numbers of children born with recurrent respiratory papillomatosis from mothers who have not been protected from genital warts through the HPV vaccination programme in each year since that programme began; and what assessment he has made of the implications for his policy of trends in those numbers.

Jane Ellison

The human papillomavirus (HPV) vaccination programme for girls was introduced in 2008, primarily to prevent cervical cancer. Initially, the bivalent vaccine Cervarix® was used that provides protection against two HPV types, HPV 16 and 18. Since September 2012, the quadrivalent vaccine Gardasil® has been used that provides protection against those two HPV types and also against two additional types, HPV 6 and 11 which cause genital warts.

The number of cases of recurrent respiratory papillomatosis that have occurred in children born to females who were vaccinated with bivalent vaccine as part of the HPV immunisation programme during 2008-2012 is unknown and has not been estimated. An assessment of the implications of this condition on vaccination policy has not been made.

Public Health England (PHE) has previously published estimates on the numbers of cancers and anogenital warts which would be prevented in males and females with a female only HPV vaccination programme. Within this work it was assumed that the use of the quadrivalent vaccine would reduce the incidence of new cases of recurrent respiratory papillomatosis at the same rate as the reduction in anogenital warts due to HPV 6 and 11, i.e. by 95% (over time). These PHE estimates assumed no reduction in genital warts (or recurrent respiratory papillomatosis) with the use of the bivalent vaccine. However, some reduction in genital warts have since been seen associated with use of the bivalent vaccine and it is therefore possible that some (smaller) reductions in recurrent respiratory papillomatosis may result from bivalent vaccine use.

The below Parliamentary question was asked by Paula Sherriff on 2016-05-03.

To ask the Secretary of State for Health, what the average rota gap is for junior doctors in NHS foundation trusts in the most recent period for which figures are available; and what assessment he has made of the effect on services of the size of that gap.

Ben Gummer

The Department does not collect this information. Rota arrangements for junior doctors are a matter for individual National Health Service foundation trusts.

Contact details for NHS foundation trusts and all other NHS authorities can be found on the NHS Choices website:

http://www.nhs.uk/nhsengland/thenhs/about/pages/authoritiesandtrusts.aspx

“

The below Parliamentary question was asked by Paula Sherriff on 2016-07-18.

To ask the Secretary of State for Health, which (a) patient transport service and (b) other contracts Coproforma holds with the NHS; and what the value is of each such contract.

David Mowat

Patient Transport Services are normally commissioned at clinical commissioning group (CCG) level. CCGs control their own budgets and hold their own contracts. Information on individual CCG contracts is not collected centrally.

The contracts with Coperforma are held by the relevant CCG as is the value of the contract. There are no central records.

The below Parliamentary question was asked by Paula Sherriff on 2016-10-10.

To ask the Secretary of State for Health, what assessment he has made of relative levels of productivity in community pharmacy and secondary care in each year since 2005.

David Mowat

We have made no assessment of productivity in community pharmacies.

The below Parliamentary question was asked by Paula Sherriff on 2015-12-17.

To ask the Secretary of State for Transport, what the planned expenditure is for the British Transport Police in (a) 2015-16, (b) 2016-17, (c) 2017-18, (d) 2018-19 and (e) 2019-20.

Claire Perry

The British Transport Police’s budget for 2015/16 is £298,078,000.

Final budgets for future years have not been established.

The below Parliamentary question was asked by Paula Sherriff on 2016-02-03.

To ask the Secretary of State for Health, if he will make an assessment of the effect on patient care and safety of planned reductions in NHS funding for community pharmacies.

Alistair Burt

Community pharmacy is a vital part of the National Health Service and can play an even greater role. In the Spending Review the Government re-affirmed the need for the NHS to deliver £22 billion in efficiency savings by 2020/21 as set out in the NHS’s own plan, the Five Year Forward View. Community pharmacy is a core part of NHS primary care and has an important contribution to make as the NHS rises to these challenges. The Government believes efficiencies can be made without compromising the quality of services or public access to them. Our aim is to ensure that those community pharmacies upon which people depend continue to thrive and so we are consulting on the introduction of a Pharmacy Access Scheme, which will provide more NHS funds to certain pharmacies compared to others, considering factors such as location and the health needs of the local population.

The Government’s vision is for a more efficient, modern system that will free up pharmacists to spend more time delivering clinical and public health services to the benefit of patients and the public.

We are consulting the Pharmaceutical Services Negotiating Committee, other pharmacy bodies and patient and public representatives on our proposals.

The below Parliamentary question was asked by Paula Sherriff on 2016-02-23.

To ask the Secretary of State for Transport, what consultations have taken place on privatisation of railway stations currently owned by Network Rail; and which stakeholders have been so consulted.

Claire Perry

Network Rail is exploring new models for station management and ownership with the goal to bring improvements for both passengers and the communities they serve. They have engaged Citigroup as advisors to consider a range of potential options but no decisions have been taken at this early stage. Any decisions on such potential future options will take account of the ‎findings of Nicola Shaw’s report into the longer term shape and financing of Network Rail.

The below Parliamentary question was asked by Paula Sherriff on 2016-03-17.

To ask Mr Chancellor of the Exchequer, with reference to paragraph 3.63 of the Spending Review and Autumn Statement 2015 and paragraph 2.16 of the Budget 2016, for what reasons the funding to support women’s charities equivalent to the annual VAT raised on sanitary products has changed from £15 million to £12 million.

Mr David Gauke

As announced at Autumn Statement 2015, the Tampon Tax Fund is a £15 million annual fund to support women’s charities, equivalent to the amount of VAT raised on sanitary products. The Chancellor announced initial donations at Autumn Statement totalling £5m. Further grants totalling £12 million have been announced at this Budget.

The Government has introduced legislation in the Finance Bill to enable the zero rate of VAT for women’s sanitary products.

The below Parliamentary question was asked by Paula Sherriff on 2016-05-03.

To ask the Secretary of State for Health, what discussions officials of his Department have had with external bodies on the development of a national liver strategy or liver framework; and if he will make a statement.

Jane Ellison

Public Health England (PHE) is producing a liver disease framework which will outline PHE’s wide range of work contributing to the prevention of liver disease and improved wellbeing for patients with liver disease. PHE is working closely with NHS England, The Lancet Commission and liver disease charities to support improvements in the quality of care for liver disease patients through the provision of information to support decision making.

The below Parliamentary question was asked by Paula Sherriff on 2016-07-18.

To ask the Secretary of State for Health, how many companies that provide patient transport services within the NHS have gone bankrupt or into administration while providing that service in each of the last five years.

Mr Philip Dunne

The Department does not hold this information.